Cargando…

Burden of mild haemophilia A: Systematic literature review

INTRODUCTION: Although the clinical manifestations of severe haemophilia A (HA) are well studied, the challenges, if any, of living with mild HA are not clearly delineated to date. AIM: To assess available evidence of clinical risks and societal/economic impacts of disease in adult patients with mil...

Descripción completa

Detalles Bibliográficos
Autores principales: Peyvandi, Flora, Tavakkoli, Fatemeh, Frame, Diana, Quinn, Jennifer, Kim, Benjamin, Lawal, Adebayo, Lee, Mimi C., Wong, Wing Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852304/
https://www.ncbi.nlm.nih.gov/pubmed/31294906
http://dx.doi.org/10.1111/hae.13777
_version_ 1783469802885480448
author Peyvandi, Flora
Tavakkoli, Fatemeh
Frame, Diana
Quinn, Jennifer
Kim, Benjamin
Lawal, Adebayo
Lee, Mimi C.
Wong, Wing Y.
author_facet Peyvandi, Flora
Tavakkoli, Fatemeh
Frame, Diana
Quinn, Jennifer
Kim, Benjamin
Lawal, Adebayo
Lee, Mimi C.
Wong, Wing Y.
author_sort Peyvandi, Flora
collection PubMed
description INTRODUCTION: Although the clinical manifestations of severe haemophilia A (HA) are well studied, the challenges, if any, of living with mild HA are not clearly delineated to date. AIM: To assess available evidence of clinical risks and societal/economic impacts of disease in adult patients with mild HA using a systematic literature review. METHODS: Prespecified study selection criteria were applied in a comprehensive literature search. Included studies varied in design and reported outcomes of interest for adults (≥13 years of age) with mild HA. RESULTS: Seventeen studies with a total of 3213 patients met eligibility criteria (published or presented in English, 1966‐2017). Most studies were observational, and the outcomes reported were too sparse and dissimilar to support a formal meta‐analysis. Mean annual bleeding rates ranged from 0.44 to 4.5 episodes per patient per year. Quality of life (QoL; SF‐36 General Health) was impacted compared to healthy controls. Health care costs and productivity were seldom assessed and no robust comparisons to healthy controls were available. CONCLUSION: Quantifying outcomes for adult patients with mild HA remains challenging, with estimates of key QoL and cost data often based on small data sets and without comparison to population norms. Therefore, the clinical impact of mild haemophilia may be under‐represented and unmet needs may remain unaddressed. As paradigm‐changing therapies for HA emerge, stronger knowledge of mild HA can guide the development of care options that minimize burden and enhance the QoL for this segment of the haemophilia community, and for the haemophilia community in totality.
format Online
Article
Text
id pubmed-6852304
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68523042019-11-22 Burden of mild haemophilia A: Systematic literature review Peyvandi, Flora Tavakkoli, Fatemeh Frame, Diana Quinn, Jennifer Kim, Benjamin Lawal, Adebayo Lee, Mimi C. Wong, Wing Y. Haemophilia Original Articles INTRODUCTION: Although the clinical manifestations of severe haemophilia A (HA) are well studied, the challenges, if any, of living with mild HA are not clearly delineated to date. AIM: To assess available evidence of clinical risks and societal/economic impacts of disease in adult patients with mild HA using a systematic literature review. METHODS: Prespecified study selection criteria were applied in a comprehensive literature search. Included studies varied in design and reported outcomes of interest for adults (≥13 years of age) with mild HA. RESULTS: Seventeen studies with a total of 3213 patients met eligibility criteria (published or presented in English, 1966‐2017). Most studies were observational, and the outcomes reported were too sparse and dissimilar to support a formal meta‐analysis. Mean annual bleeding rates ranged from 0.44 to 4.5 episodes per patient per year. Quality of life (QoL; SF‐36 General Health) was impacted compared to healthy controls. Health care costs and productivity were seldom assessed and no robust comparisons to healthy controls were available. CONCLUSION: Quantifying outcomes for adult patients with mild HA remains challenging, with estimates of key QoL and cost data often based on small data sets and without comparison to population norms. Therefore, the clinical impact of mild haemophilia may be under‐represented and unmet needs may remain unaddressed. As paradigm‐changing therapies for HA emerge, stronger knowledge of mild HA can guide the development of care options that minimize burden and enhance the QoL for this segment of the haemophilia community, and for the haemophilia community in totality. John Wiley and Sons Inc. 2019-07-11 2019-09 /pmc/articles/PMC6852304/ /pubmed/31294906 http://dx.doi.org/10.1111/hae.13777 Text en © 2019 The Authors. Haemophilia Published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Peyvandi, Flora
Tavakkoli, Fatemeh
Frame, Diana
Quinn, Jennifer
Kim, Benjamin
Lawal, Adebayo
Lee, Mimi C.
Wong, Wing Y.
Burden of mild haemophilia A: Systematic literature review
title Burden of mild haemophilia A: Systematic literature review
title_full Burden of mild haemophilia A: Systematic literature review
title_fullStr Burden of mild haemophilia A: Systematic literature review
title_full_unstemmed Burden of mild haemophilia A: Systematic literature review
title_short Burden of mild haemophilia A: Systematic literature review
title_sort burden of mild haemophilia a: systematic literature review
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852304/
https://www.ncbi.nlm.nih.gov/pubmed/31294906
http://dx.doi.org/10.1111/hae.13777
work_keys_str_mv AT peyvandiflora burdenofmildhaemophiliaasystematicliteraturereview
AT tavakkolifatemeh burdenofmildhaemophiliaasystematicliteraturereview
AT framediana burdenofmildhaemophiliaasystematicliteraturereview
AT quinnjennifer burdenofmildhaemophiliaasystematicliteraturereview
AT kimbenjamin burdenofmildhaemophiliaasystematicliteraturereview
AT lawaladebayo burdenofmildhaemophiliaasystematicliteraturereview
AT leemimic burdenofmildhaemophiliaasystematicliteraturereview
AT wongwingy burdenofmildhaemophiliaasystematicliteraturereview